Edoxaban monotherapy lowered the risk of adverse outcomes, including death from any cause, myocardial infarction, stroke, and systemic embolism at 12 months compared to the dual antithrombotic therapy approach in patients with atrial fibrillation and stable coronary artery disease.
Katsuyoshi Sugita, chief people officer and chief ethics and compliance officer at Astellas Pharma, discusses innovative methods that are improving DE&I in the industry.
Latest Phase II data of Valneva and Pfizer’s VLA15 are consistent with those reported following the first booster dose.
The first-in-class, investigational RNA interference drug plozasiran was found to lower triglyceride levels and incidence of pancreatitis compared to placebo in patients with persistent chylomicronemia, including patients with familial chylomicronemia syndrome.
In the final part of this video interview, Jim Murphy, CEO of Greenphire discusses the role of artificial intelligence, using trusted data, and simplifying protocols.
First FDA submission of nipocalimab is based on positive results from the Phase III Vivacity-MG3 program.
According to a recent Phase II clinical trial conducted by Johns Hopkins Kimmel Cancer Center, all enrolled patients experienced a prostate-specific antigen reduction of 50% or more when treated with Olaparib.
Maximizing the impact of data is only possible when strong fundamental data management capabilities are in place.
In part 4 of this video interview, Jim Murphy, CEO of Greenphire highlights some trends he is currently seeing such as travel reimbursement and minimizing out of pocket costs.
The Phase III V-MONO clinical trial met its primary endpoints, demonstrating Leqvio (inclisiran) monotherapy as superior to placebo and ezetimibe.
Crinecerfont was granted previously granted FDA Priority Review designation to treat children, adolescents, and adults with classic congenital adrenal hyperplasia.
In part 3 of this video interview, Jim Murphy, CEO of Greenphire addresses the increasing complexity of trial protocols and how it is affecting patient access.
In part 2 of this video interview, Jim Murphy, CEO of Greenphire discusses how access to data can impact elements such as budgeting and enrollment.
The clinical program consists of two studies, MELODY-2 and MELODY-3, from which results are expected in Q4 2025.
Cohort study finds a superior tolerability profile with darolutamide compared to other androgen receptor inhibitors, which investigators said indicates an efficacy advantage in the treatment of nonmetastatic castration-resistant prostate cancer.
In the first part of this video interview, Jim Murphy, CEO of Greenphire touches on how changing trends in enrollment are creating obstacles with modeling costs.
First-in-class option to reduce frequency and severity of VMS due to menopause will now be evaluated in women with breast cancer receiving adjuvant endocrine therapy.
Investigators conclude that policies seeking to lower rates of diabetes may also contribute to the goal of ending tuberculosis.
Observational cohort study evaluated nearly 900 school-age children to identify how these symptoms vary by age and how they can assist in future research of long COVID.
New vaccine is tailored to the KP.2 strain, based on regulatory guidance for upcoming fall and winter season.
Elinzanetant was found to significantly lower the frequency and severity of moderate to severe vasomotor symptoms with statistically significant improvements in sleep disturbances and menopause-related quality of life.
Trial will evaluate Galapagos’ GLPG5101, an autologous CD19 CAR-T cell therapy product candidate.
Mild or moderate acute kidney injury has been linked to increased morbidity and mortality, with a greater risk of chronic kidney disease in patients who undergo cardiac surgery with cardiopulmonary bypass.
In the third and final part of this conversation, Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara sheds light on industry collaboration and what elements of trial design have the greatest impact on diversity.
The pivotal Phase III OASIS 1 and 2 studies both met all primary endpoints with elinzanetan reducing symptoms over 12 weeks compared to placebo.
In part 2 of this conversation, Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses the guidance and how it will affect sponsors moving forward.
A higher percentage of patients with advanced clear-cell renal cell carcinoma administered Welireg were alive and without disease progression compared to everolimus at 12 and 18 months.
In part 1 of this video interview, Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara highlights how IROs are bringing care directly to patients and making them feel more comfortable.
The Tufts Center for the Study of Drug Development (Tufts CSDD) is conducting a study on investigative site perspectives and burden associated with Direct-to-Patient (DTP) shipment of study treatments and supplies.
Phase III REST-ON trial data show higher rates of weight loss in patients administered Lumryz to treat both narcolepsy type 1 (with cataplexy) and narcolepsy type 2 (without cataplexy) compared with placebo.
